ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress

Share Article

Clinical Financial Best Practices Will Be Discussed and Demonstrated at Philadelphia Conference

Industry Performance Review and Strategies for Communicating Key Financial Information and Disclosures

ClearTrial, the leading provider of Clinical Trial Operations (CTO) software, today announced it will moderate a panel discussion which includes pharmaceutical analysts from Deutsche Bank and Cowen & Company at CBI's 2010 Accounting and Reporting Congress in Philadelphia, Pennsylvania, March 16-17. This conference is attended each year by over 300 finance, accounting, audit and reporting executives seeking information about changing regulations, technical accounting guidelines, auditing strategies and financial reporting best practices.

At this year's conference, participants will hear from an unparalleled assembly of over 35 speakers representing the pharmaceutical and biotechnology industries. Michael Bruns, CFO at ClearTrial, was chosen to moderate the Wall Street Panel, "Industry Performance Review and Strategies for Communicating Key Financial Information and Disclosures" on March 17th at 9:15 am. This panel discussion will provide perspectives from Wall Street on the pharmaceutical sector and key performance indicators. Attendees will learn best practices for investor calls, financial disclosures and overall communications regarding financial positions while gaining insight on industry trends and overall industry market perception from senior life science sector industry analysts.

Prior to joining ClearTrial, Mr. Bruns founded and directed the Technology and Investment Banking group at Robert W. Baird & Co., a global investment banking firm. He led the group's business development efforts and advised executive management teams and boards of directors of public and private company clients on corporate strategy, acquisition strategy and corporate finance alternatives.

Attendees can also visit ClearTrial in the exhibit hall to see practical demonstrations of how some of the world's leading Pharmaceutical and Biotech companies are using ClearTrial as the foundation for their innovative Clinical Financial Best Practices.

By attending these demonstrations, attendees will learn how to:

  • Accurately track accruals and reforecast for change orders
  • Gain insight into cost variances and underperforming projects
  • Determine when to outsource
  • Recognize cost savings within collaborative arrangements
  • Anticipate study costs for both in-licensing and out-licensing agreements

CBI's 2010 Accounting and Reporting Congress event will be held at the Loews Hotel, Philadelphia, PA on March 16-17. For more information and to register for the conference, visit http://www.cbinet.com/show_conference.cfm?confcode=PC10139.

About ClearTrial®
ClearTrial is the leading provider of Clinical Trial Operations (CTO) software, an integrated system for clinical operations planning, forecasting, outsourcing, and project tracking. ClearTrial's award-winning software helps life sciences companies streamline their clinical operations from Plan to Payment™ without sacrificing quality of results, providing executives and functional leaders in clinical operations, resource planning, finance, outsourcing, and project management with a common platform that promotes speed, accuracy, and consistency throughout the organization. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

For more information contact:
Nicole Fitzmaurice
ClearTrial
+1 630.986.9800 x131
nfitzmaurice(at)cleartrial(dot)com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicole Fitzmaurice
ClearTrial
630-986-9800 ext. 131
Email >
Visit website